EMEA (Europe, Middle East and Africa) Conjugate Vaccine Market Report 2017

December 2017 | 101 pages | ID: EF2D6AC3D56EN
QYResearch

Abstracts

In this report, the EMEA Conjugate Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Conjugate Vaccine for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Conjugate Vaccine market competition by top manufacturers/players, with Conjugate Vaccine sales volume (K MT), price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Bharat Biotech (India)
• Biological E (India)
• CSL Limited (Australia)
• GlaxoSmithKline (U.K.)
• Merck and Company (U.S.)
• Neuron Biotech (U.S.)
• Novartis AG (Switzerland)
• Pfizer (U.S.)
• Sanofi Pasteur (France)

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• By Disease Indication
• Pneumococcal
• Influenza
• Diphtheria Tetanus Pertussis
• Meningococcal
• By Type
• Monovalent
• Multivalen
• By Patient Stage

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital
• Medical Center

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Conjugate Vaccine Market Report 2017

1 CONJUGATE VACCINE OVERVIEW

1.1 Product Overview and Scope of Conjugate Vaccine
1.2 Classification of Conjugate Vaccine
  1.2.1 EMEA Conjugate Vaccine Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Conjugate Vaccine Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Pneumococcal
  1.2.4 Influenza
  1.2.5 Diphtheria Tetanus Pertussis
  1.2.6 Meningococcal
1.3 EMEA Conjugate Vaccine Market by Application/End Users
  1.3.1 EMEA Conjugate Vaccine Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospital
  1.3.3 Medical Center
1.4 EMEA Conjugate Vaccine Market by Region
  1.4.1 EMEA Conjugate Vaccine Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Conjugate Vaccine (2012-2022)
  1.5.1 EMEA Conjugate Vaccine Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Conjugate Vaccine Revenue and Growth Rate (2012-2022)

2 EMEA CONJUGATE VACCINE COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Conjugate Vaccine Market Competition by Players/Manufacturers
  2.1.1 EMEA Conjugate Vaccine Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Conjugate Vaccine Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Conjugate Vaccine Sale Price by Players (2012-2017)
2.2 EMEA Conjugate Vaccine (Volume and Value) by Type/Product Category
  2.2.1 EMEA Conjugate Vaccine Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Conjugate Vaccine Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Conjugate Vaccine Sale Price by Type (2012-2017)
2.3 EMEA Conjugate Vaccine (Volume) by Application
2.4 EMEA Conjugate Vaccine (Volume and Value) by Region
  2.4.1 EMEA Conjugate Vaccine Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Conjugate Vaccine Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Conjugate Vaccine Sales Price by Region (2012-2017)

3 EUROPE CONJUGATE VACCINE (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Conjugate Vaccine Sales and Value (2012-2017)
  3.1.1 Europe Conjugate Vaccine Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Conjugate Vaccine Revenue and Growth Rate (2012-2017)
3.2 Europe Conjugate Vaccine Sales and Market Share by Type
3.3 Europe Conjugate Vaccine Sales and Market Share by Application
3.4 Europe Conjugate Vaccine Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Conjugate Vaccine Sales Volume by Countries (2012-2017)
  3.4.2 Europe Conjugate Vaccine Revenue by Countries (2012-2017)
  3.4.3 Germany Conjugate Vaccine Sales and Growth Rate (2012-2017)
  3.4.4 France Conjugate Vaccine Sales and Growth Rate (2012-2017)
  3.4.5 UK Conjugate Vaccine Sales and Growth Rate (2012-2017)
  3.4.6 Russia Conjugate Vaccine Sales and Growth Rate (2012-2017)
  3.4.7 Italy Conjugate Vaccine Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Conjugate Vaccine Sales and Growth Rate (2012-2017)

4 MIDDLE EAST CONJUGATE VACCINE (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Conjugate Vaccine Sales and Value (2012-2017)
  4.1.1 Middle East Conjugate Vaccine Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Conjugate Vaccine Revenue and Growth Rate (2012-2017)
4.2 Middle East Conjugate Vaccine Sales and Market Share by Type
4.3 Middle East Conjugate Vaccine Sales and Market Share by Application
4.4 Middle East Conjugate Vaccine Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Conjugate Vaccine Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Conjugate Vaccine Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Conjugate Vaccine Sales and Growth Rate (2012-2017)
  4.4.4 Israel Conjugate Vaccine Sales and Growth Rate (2012-2017)
  4.4.5 UAE Conjugate Vaccine Sales and Growth Rate (2012-2017)
  4.4.6 Iran Conjugate Vaccine Sales and Growth Rate (2012-2017)

5 AFRICA CONJUGATE VACCINE (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Conjugate Vaccine Sales and Value (2012-2017)
  5.1.1 Africa Conjugate Vaccine Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Conjugate Vaccine Revenue and Growth Rate (2012-2017)
5.2 Africa Conjugate Vaccine Sales and Market Share by Type
5.3 Africa Conjugate Vaccine Sales and Market Share by Application
5.4 Africa Conjugate Vaccine Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Conjugate Vaccine Sales Volume by Countries (2012-2017)
  5.4.2 Africa Conjugate Vaccine Revenue by Countries (2012-2017)
  5.4.3 South Africa Conjugate Vaccine Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Conjugate Vaccine Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Conjugate Vaccine Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Conjugate Vaccine Sales and Growth Rate (2012-2017)

6 EMEA CONJUGATE VACCINE MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Bharat Biotech (India)
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Conjugate Vaccine Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Bharat Biotech (India) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Biological E (India)
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Conjugate Vaccine Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Biological E (India) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 CSL Limited (Australia)
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Conjugate Vaccine Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 CSL Limited (Australia) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 GlaxoSmithKline (U.K.)
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Conjugate Vaccine Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 GlaxoSmithKline (U.K.) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Merck and Company (U.S.)
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Conjugate Vaccine Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Merck and Company (U.S.) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Neuron Biotech (U.S.)
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Conjugate Vaccine Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Neuron Biotech (U.S.) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Novartis AG (Switzerland)
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Conjugate Vaccine Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Novartis AG (Switzerland) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Pfizer (U.S.)
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Conjugate Vaccine Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Pfizer (U.S.) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Sanofi Pasteur (France)
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Conjugate Vaccine Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Sanofi Pasteur (France) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview

7 CONJUGATE VACCINE MANUFACTURING COST ANALYSIS

7.1 Conjugate Vaccine Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Conjugate Vaccine

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Conjugate Vaccine Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Conjugate Vaccine Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA CONJUGATE VACCINE MARKET FORECAST (2017-2022)

11.1 EMEA Conjugate Vaccine Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Conjugate Vaccine Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Conjugate Vaccine Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Conjugate Vaccine Price and Trend Forecast (2017-2022)
11.2 EMEA Conjugate Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Conjugate Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Conjugate Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Conjugate Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Conjugate Vaccine Sales Forecast by Type (2017-2022)
11.7 EMEA Conjugate Vaccine Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Conjugate Vaccine
Figure EMEA Conjugate Vaccine Sales Volume (K MT) by Type (2012-2022)
Figure EMEA Conjugate Vaccine Sales Volume Market Share by Type (Product Category) in 2016
Figure Pneumococcal Product Picture
Figure Influenza Product Picture
Figure Diphtheria Tetanus Pertussis Product Picture
Figure Meningococcal Product Picture
Figure EMEA Conjugate Vaccine Sales Volume (K MT) by Application (2012-2022)
Figure EMEA Sales Market Share of Conjugate Vaccine by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Medical Center Examples
Table Key Downstream Customer in Medical Center
Figure EMEA Conjugate Vaccine Market Size (Million USD) by Region (2012-2022)
Figure Europe Conjugate Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Conjugate Vaccine Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Conjugate Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Conjugate Vaccine Revenue (Million USD) Status and Forecast by Countries
Figure Africa Conjugate Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Conjugate Vaccine Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Conjugate Vaccine Sales Volume and Growth Rate (2012-2022)
Figure EMEA Conjugate Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Conjugate Vaccine Market Major Players Product Sales Volume (K MT) (2012-2017)
Table EMEA Conjugate Vaccine Sales Volume (K MT) of Major Players (2012-2017)
Table EMEA Conjugate Vaccine Sales Share by Players (2012-2017)
Figure 2016 Conjugate Vaccine Sales Share by Players
Figure 2017 Conjugate Vaccine Sales Share by Players
Figure EMEA Conjugate Vaccine Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Conjugate Vaccine Revenue (Million USD) by Players (2012-2017)
Table EMEA Conjugate Vaccine Revenue Share by Players (2012-2017)
Table 2016 EMEA Conjugate Vaccine Revenue Share by Players
Table 2017 EMEA Conjugate Vaccine Revenue Share by Players
Table EMEA Conjugate Vaccine Sale Price (USD/MT) by Players (2012-2017)
Table EMEA Conjugate Vaccine Sales (K MT) and Market Share by Type (2012-2017)
Table EMEA Conjugate Vaccine Sales Share by Type (2012-2017)
Figure Sales Market Share of Conjugate Vaccine by Type (2012-2017)
Figure EMEA Conjugate Vaccine Sales Market Share by Type (2012-2017)
Table EMEA Conjugate Vaccine Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Conjugate Vaccine Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Conjugate Vaccine by Type in 2016
Table EMEA Conjugate Vaccine Sale Price (USD/MT) by Type (2012-2017)
Table EMEA Conjugate Vaccine Sales (K MT) and Market Share by Application (2012-2017)
Table EMEA Conjugate Vaccine Sales Share by Application (2012-2017)
Figure Sales Market Share of Conjugate Vaccine by Application (2012-2017)
Figure EMEA Conjugate Vaccine Sales Market Share by Application in 2016
Table EMEA Conjugate Vaccine Sales (K MT) and Market Share by Region (2012-2017)
Table EMEA Conjugate Vaccine Sales Share by Region (2012-2017)
Figure Sales Market Share of Conjugate Vaccine by Region (2012-2017)
Figure EMEA Conjugate Vaccine Sales Market Share in 2016
Table EMEA Conjugate Vaccine Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Conjugate Vaccine Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Conjugate Vaccine by Region (2012-2017)
Figure EMEA Conjugate Vaccine Revenue Market Share Regions in 2016
Table EMEA Conjugate Vaccine Sales Price (USD/MT) by Region (2012-2017)
Figure Europe Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Europe Conjugate Vaccine Revenue and Growth Rate (2012-2017)
Table Europe Conjugate Vaccine Sales (K MT) by Type (2012-2017)
Table Europe Conjugate Vaccine Market Share by Type (2012-2017)
Figure Europe Conjugate Vaccine Market Share by Type in 2016
Table Europe Conjugate Vaccine Sales (K MT) by Application (2012-2017)
Table Europe Conjugate Vaccine Market Share by Application (2012-2017)
Figure Europe Conjugate Vaccine Market Share by Application in 2016
Table Europe Conjugate Vaccine Sales (K MT) by Countries (2012-2017)
Table Europe Conjugate Vaccine Sales Market Share by Countries (2012-2017)
Figure Europe Conjugate Vaccine Sales Market Share by Countries (2012-2017)
Figure Europe Conjugate Vaccine Sales Market Share by Countries in 2016
Table Europe Conjugate Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Europe Conjugate Vaccine Revenue Market Share by Countries (2012-2017)
Figure Europe Conjugate Vaccine Revenue Market Share by Countries (2012-2017)
Figure Europe Conjugate Vaccine Revenue Market Share by Countries in 2016
Figure Germany Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure France Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure UK Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Russia Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Italy Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Benelux Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Middle East Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Middle East Conjugate Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Conjugate Vaccine Sales (K MT) by Type (2012-2017)
Table Middle East Conjugate Vaccine Market Share by Type (2012-2017)
Figure Middle East Conjugate Vaccine Market Share by Type (2012-2017)
Table Middle East Conjugate Vaccine Sales (K MT) by Applications (2012-2017)
Table Middle East Conjugate Vaccine Market Share by Applications (2012-2017)
Figure Middle East Conjugate Vaccine Sales Market Share by Application in 2016
Table Middle East Conjugate Vaccine Sales Volume (K MT) by Countries (2012-2017)
Table Middle East Conjugate Vaccine Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Conjugate Vaccine Sales Volume Market Share by Countries in 2016
Table Middle East Conjugate Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Middle East Conjugate Vaccine Revenue Market Share by Countries (2012-2017)
Figure Middle East Conjugate Vaccine Revenue Market Share by Countries (2012-2017)
Figure Middle East Conjugate Vaccine Revenue Market Share by Countries in 2016
Figure Saudi Arabia Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Israel Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure UAE Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Iran Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Africa Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Africa Conjugate Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Conjugate Vaccine Sales (K MT) by Type (2012-2017)
Table Africa Conjugate Vaccine Sales Market Share by Type (2012-2017)
Figure Africa Conjugate Vaccine Sales Market Share by Type (2012-2017)
Figure Africa Conjugate Vaccine Sales Market Share by Type in 2016
Table Africa Conjugate Vaccine Sales (K MT) by Application (2012-2017)
Table Africa Conjugate Vaccine Sales Market Share by Application (2012-2017)
Figure Africa Conjugate Vaccine Sales Market Share by Application (2012-2017)
Table Africa Conjugate Vaccine Sales Volume (K MT) by Countries (2012-2017)
Table Africa Conjugate Vaccine Sales Market Share by Countries (2012-2017)
Figure Africa Conjugate Vaccine Sales Market Share by Countries (2012-2017)
Figure Africa Conjugate Vaccine Sales Market Share by Countries in 2016
Table Africa Conjugate Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Africa Conjugate Vaccine Revenue Market Share by Countries (2012-2017)
Figure Africa Conjugate Vaccine Revenue Market Share by Countries (2012-2017)
Figure Africa Conjugate Vaccine Revenue Market Share by Countries in 2016
Figure South Africa Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Nigeria Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Egypt Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Algeria Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Table Bharat Biotech (India) Conjugate Vaccine Basic Information List
Table Bharat Biotech (India) Conjugate Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Bharat Biotech (India) Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Bharat Biotech (India) Conjugate Vaccine Sales Market Share in EMEA (2012-2017)
Figure Bharat Biotech (India) Conjugate Vaccine Revenue Market Share in EMEA (2012-2017)
Table Biological E (India) Conjugate Vaccine Basic Information List
Table Biological E (India) Conjugate Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Biological E (India) Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Biological E (India) Conjugate Vaccine Sales Market Share in EMEA (2012-2017)
Figure Biological E (India) Conjugate Vaccine Revenue Market Share in EMEA (2012-2017)
Table CSL Limited (Australia) Conjugate Vaccine Basic Information List
Table CSL Limited (Australia) Conjugate Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure CSL Limited (Australia) Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure CSL Limited (Australia) Conjugate Vaccine Sales Market Share in EMEA (2012-2017)
Figure CSL Limited (Australia) Conjugate Vaccine Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline (U.K.) Conjugate Vaccine Basic Information List
Table GlaxoSmithKline (U.K.) Conjugate Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure GlaxoSmithKline (U.K.) Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure GlaxoSmithKline (U.K.) Conjugate Vaccine Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline (U.K.) Conjugate Vaccine Revenue Market Share in EMEA (2012-2017)
Table Merck and Company (U.S.) Conjugate Vaccine Basic Information List
Table Merck and Company (U.S.) Conjugate Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Merck and Company (U.S.) Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Merck and Company (U.S.) Conjugate Vaccine Sales Market Share in EMEA (2012-2017)
Figure Merck and Company (U.S.) Conjugate Vaccine Revenue Market Share in EMEA (2012-2017)
Table Neuron Biotech (U.S.) Conjugate Vaccine Basic Information List
Table Neuron Biotech (U.S.) Conjugate Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Neuron Biotech (U.S.) Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Neuron Biotech (U.S.) Conjugate Vaccine Sales Market Share in EMEA (2012-2017)
Figure Neuron Biotech (U.S.) Conjugate Vaccine Revenue Market Share in EMEA (2012-2017)
Table Novartis AG (Switzerland) Conjugate Vaccine Basic Information List
Table Novartis AG (Switzerland) Conjugate Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Novartis AG (Switzerland) Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Novartis AG (Switzerland) Conjugate Vaccine Sales Market Share in EMEA (2012-2017)
Figure Novartis AG (Switzerland) Conjugate Vaccine Revenue Market Share in EMEA (2012-2017)
Table Pfizer (U.S.) Conjugate Vaccine Basic Information List
Table Pfizer (U.S.) Conjugate Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Pfizer (U.S.) Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Pfizer (U.S.) Conjugate Vaccine Sales Market Share in EMEA (2012-2017)
Figure Pfizer (U.S.) Conjugate Vaccine Revenue Market Share in EMEA (2012-2017)
Table Sanofi Pasteur (France) Conjugate Vaccine Basic Information List
Table Sanofi Pasteur (France) Conjugate Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Sanofi Pasteur (France) Conjugate Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Sanofi Pasteur (France) Conjugate Vaccine Sales Market Share in EMEA (2012-2017)
Figure Sanofi Pasteur (France) Conjugate Vaccine Revenue Market Share in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Conjugate Vaccine
Figure Manufacturing Process Analysis of Conjugate Vaccine
Figure Conjugate Vaccine Industrial Chain Analysis
Table Raw Materials Sources of Conjugate Vaccine Major Manufacturers in 2016
Table Major Buyers of Conjugate Vaccine
Table Distributors/Traders List
Figure EMEA Conjugate Vaccine Sales (K MT) and Growth Rate Forecast (2017-2022)
Figure EMEA Conjugate Vaccine Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Conjugate Vaccine Price (USD/MT) and Trend Forecast (2017-2022)
Table EMEA Conjugate Vaccine Sales (K MT) Forecast by Region (2017-2022)
Figure EMEA Conjugate Vaccine Sales Market Share Forecast by Region (2017-2022)
Table EMEA Conjugate Vaccine Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Conjugate Vaccine Revenue Market Share Forecast by Region (2017-2022)
Table Europe Conjugate Vaccine Sales (K MT) Forecast by Countries (2017-2022)
Figure Europe Conjugate Vaccine Sales Market Share Forecast by Countries (2017-2022)
Table Europe Conjugate Vaccine Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Conjugate Vaccine Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Conjugate Vaccine Sales (K MT) Forecast by Countries (2017-2022)
Figure Middle East Conjugate Vaccine Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Conjugate Vaccine Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Conjugate Vaccine Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Conjugate Vaccine Sales (K MT) Forecast by Countries (2017-2022)
Figure Africa Conjugate Vaccine Sales Market Share Forecast by Countries (2017-2022)
Table Africa Conjugate Vaccine Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Conjugate Vaccine Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Conjugate Vaccine Sales (K MT) Forecast by Type (2017-2022)
Figure EMEA Conjugate Vaccine Sales Market Share Forecast by Type (2017-2022)
Table EMEA Conjugate Vaccine Sales (K MT) Forecast by Application (2017-2022)
Figure EMEA Conjugate Vaccine Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources